RxDoctor Payments Data

Manisha Kumar, DO

Rheumatology · San Diego, CANPI 1164524088

Payments from drug & device makers

$1,969in general payments, 2019–2025

Across 86 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$982
  • AbbVie$159
  • Pfizer$137
  • Genentech USA, Inc.$128
  • Janssen Scientific Affairs, LLC$119
  • AstraZeneca$113
  • plus $331 from 6 others

What the payments were for

  • Food & beverage$1,969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,969 in reported general payments places this provider in the 45th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$3,195,692
Medicare patients
830
Services billed
152,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept47$378,107
Humira(Cf) PenAdalimumab35$298,261
RemicadeInfliximab13$99,406
OtezlaApremilast13$72,653
Xeljanz XrTofacitinib Citrate13$71,117
ProliaDenosumab20$32,694
Hydroxychloroquine Sulfate89$6,608
MethotrexateMethotrexate Sodium131$5,010
Cevimeline Hcl11$3,072
Gabapentin87$2,785
Prednisone294$2,506
Duloxetine Hcl65$1,975
Diclofenac Sodium28$1,393
Celecoxib22$1,074
Leflunomide11$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Prolia$982$105,34633 claims
Johnson & JohnsonRemicade$34$99,40613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 808 rheumatology providers in California.

Other rheumatology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →